Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
|
|
- Paulina Phelps
- 6 years ago
- Views:
Transcription
1 Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Monitoring Patients for TB Adverse Reactions and Managing Side Effects Catalina Navarro, RN, BSN April 11, 2014 Catalina Navarro, RN, BSN has the following disclosures to make: No conflict of interests No relevant financial relationships with any commercial companies pertaining to this educational activity 1
2 Monitoring Patients for TB Meds Adverse Reactions and Managing Side Effects Catalina Navarro RN BSN TB Nurse Consultant/Educator Objectives Describe the monitoring process for adverse drug events Discuss side effects and drug toxicities Recognize the most common adverse drug events Discuss the nursing interventions and medical management of the most common adverse drug events 2
3 Goals of TB Treatment Cure the patient Minimize the risk of death & disability Reduce transmission NOTE: Responsibility of successful treatment is assigned to the health care provider NOT THE PATIENT Purpose of Monitoring Patient Recognize adverse drug events Assess appropriately Intervene rapidly Prevent further morbidity/mortality Minimize treatment interruptions Reduce opportunities for medical mismanagement Avoid development of psychological intolerance Support adherence and the therapeutic relationship 3
4 Side Effects Occur in addition to the desired therapeutic effect Unpleasant, but mild reactions No long lasting health effects Do not usually require changes in therapy Adverse Drug Reaction More serious May be life threatening Require modifying the dose/discontinuation of drug May require additional therapy and/or hospitalization 4
5 Side Effects Adverse Drug Reaction Gas Bloating Mild nausea Discoloration of body fluids Irritability Difficulty sleeping Photosensitivity Significant GI disturbances Dermatologic/ hypersensitivity reactions Ophthalmic toxicity CNS toxicity Neurotoxicity Ototoxicity Musculoskeletal Renal toxicity All Medications Have Side Effects Most TB patients complete their treatment without any significant adverse drug effects Risk/Benefit ratio of medication used Explain beneficial effects of medications and possible side effects/adverse events The benefits provided by the medicine worth the risk 5
6 ? Possible side effects of acetaminophen Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop taking this medication and call your doctor at once if you have a serious side effect such as: low fever with nausea, stomach pain, and loss of appetite; dark urine, clay-colored stools; or jaundice (yellowing of the skin or eyes). This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA. Benefits Vs. Risks 6
7 Don t Forget: Explain to patient that there will be side effects to the medications - but you will work with them to manage them Patient education & charting of education First-line Drugs Isoniazid (INH) Rifampin (RIF) Rifabutin Ethambutol (EMB) Pyrazinamide (PZA) 7
8 Side Effects of First Line Drugs INH G.I. upset Peripheral neuropathy PZA G.I. upset Arthralgias Gout (rare Rifampin G.I. upset Thrombocytopenia, hemolytic anemia Renal toxicity Flu-like syndrome Orange staining of body fluids Optic Neuritis Ethambutol Rifabutin /Skin discoloration Leukopenia Thrombocytopenia Uveitis Arthralgias 8
9 Peripheral Neuropathy Tingling, prickling & burning balls of feet or tips of toes More likely: Diabetic, alcoholic, HIV infection, pregnancy, poor nutrition, hypothyroidism Sensory loss can occur; ankle reflexes lost; unsteady painful gait Can progress to the fingers and hands Administer Vitamin B6 (pyridoxine) 50mg daily Note: B6 in doses greater than 200mg can CAUSE neuropathy Musculoskeletal Adverse Effects Aches & Pains Variety of TB meds can cause INH, PZA, Rifabutin, fluroquinolones Do Not Stop meds NSAIDS can be helpful 9
10 Gastrointestinal (GI) Upset Gastro Intestinal Upset INH G.I. upset Peripheral neuropathy Mild CNS Toxicity Rifampin G.I. upset Thrombocytopenia, hemolytic anemia Renal toxicity Flu-like syndrome Orange staining of body fluids Rifabutin /Skin discoloration Leukopenia Thrombocytopenia Uveitis Arthralgias PZA G.I. upset Arthralgias Gout (rare Ethambutol Optic Neuritis 10
11 Gastrointestinal Upset Nausea/vomiting/diarrhea (NVD) Common in the first few weeks of therapy Give a light snack before meds Gastrointestinal (GI) Upset Administer antiemetic Phenergan Zofran Plasil Administer antacids but NOT given within 2 hours of fluoroquinolones Encourage hydration ( Sports drinks electrolyte replacement) 11
12 Monitoring Gastrointestinal (GI) Upset Evaluate the interventions Nausea decreased? Persistent throughout the day? May need to stop the offending medication Is there an adequate replacement? If no, patient may need to tolerate some n/v. If yes, consider switching medication May need expert consultation before switching meds Hepatotoxicity 12
13 Hepatotoxicity with First Line Drugs INH G.I. upset Peripheral neuropathy Mild CNS Toxicity PZA G.I. upset Arthralgias Gout (rare Rifampin G.I. upset Thrombocytopenia, hemolytic anemia Renal toxicity Flu-like syndrome Orange staining of body fluids Ethambutol Optic Neuritis Rifabutin /Skin discoloration Leukopenia Thrombocytopenia Uveitis Arthralgias Hepatotoxicity Early Signs Fatigue Poor appetite Taste alteration Nausea Abdominal discomfort Bloating Minimal rash Later Signs Vomiting Abdominal pain Jaundice Change in color of urine and stool Changes in behavior, memory loss 13
14 Risk Factors for Hepatotoxicity Underlying liver disease Hepatitis B and C Alcoholism Immediate (4 months) post-partum period Hepatotoxic medications Hepatotoxic Drugs Tylenol Tetracycline, erythromycin, others Dilantin Valproate Cholesterol lowering medications Antifungal drugs Glucose lowering drugs Valium 14
15 Monitoring Medical history Preexisting conditions may increase hepatotoxicity History of Hepatitis B or C History of other liver disease Social history ETOH use (be specific) Educate patient of signs and symptoms of hepatotoxicity Managing Hepatotoxicity Check Liver Function Test (LFT) at baseline and monthly Stop therapy LFT s> 3 times upper limit of normal and symptomatic LFTs> 5 times upper limit of normal and asymptomatic 15
16 Re-Challenge Restarting therapy LFT s must be < 2 times upper limit of normal Rechallenge Medications Introduce one drug at a time Monitor enzymes carefully Stop therapy if symptomatic or increased enzymes Eliminate last drug added from regimen 16
17 Case Study #1 65 y/o female diagnosed with PTB on December 2013 Chest X-ray abnormal AFB smear (+) NAAT (+) Culture pending Baseline labs WNL RIPE started on December 16 th Re-Challenge? December January February INH RIF PZA EMB LFT s WNL 2xUNL >3xUNL 2xUNL WNL WNL 5xUNL 17
18 Case Study #2 35 y/o male diagnosed with PTB on February 2014 Chest X-ray abnormal AFB smear (+) NAAT (+) Culture pending Baseline labs WNL RIPE started on March 10 th LFT s WNL 18
19 Re-Challenge TB Meds (Hepatotoxicity) FEBRUARY MARCH APRIL INH RIF PZA EMB WNL >3x UNL>2x UNL WNL Rechallenge TB Meds (Hepatotoxicity) APRIL MAY JUNE JULY RIF INH PZA EMB LFT s WNL WNL WNL >3xUNL 2xUNL WNL 19
20 Rechallenge TB Meds (Hepatotoxicity) APRIL MAY JUNE JULY RIF INH 9 months of Rx. PZA EMB Pansuscep. LFT s WNL WNL WNL WNL Rash 20
21 Rash INH G.I. upset Peripheral neuropathy Mild CNS Toxicity PZA G.I. upset Arthralgias Gout (rare Rifampin G.I. upset Thrombocytopenia, hemolytic anemia Renal toxicity Flu-like syndrome Orange staining of body fluids Ethambutol Optic Neuritis Rifabutin /Skin discoloration Leukopenia Thrombocytopenia Uveitis Arthralgias Evaluate the Rash Where is it? What does it look like? Does it itch? When did it start? Has it spread? What makes it better or worse? Have you had an insect bite? 21
22 Other Possible Causes Insect bites Scabies Contact dermatitis Question patient about new soaps, lotions, perfumes, laundry detergents, etc Sunburn Dry skin Other drugs, especially new agents Viral or fungal infections Common Mild Rash Often resolve after first several weeks of treatment Usually do not require stopping medication Treated symptomatically with Benadryl, other antihistamines, low-dose prednisone 22
23 Rash: Hypersensitive Reaction Petechial Rash Thrombocytopenia with Rifampin Do platelet count What was the baseline? If low suspect hypersensitive reaction to Rifampin Consult with clinician STOP Rifampin monitor platelets until normal Rifampin should not be restarted Additional medication will need to be added Will increase treatment length w/o Rifampin May need expert medical consultation Rash: Hypersensitive Reaction Generalized erythematous rash: Assoc with fever OR mucous membrane involvement STOPTB medications call clinician If Anaphylaxis call 911 Drug re-challenge If no anaphylaxis or airway compromise May consider drug re-challenge See Drug Resistant TB Curry National TB Center p
24 Rifabutin Decreased WBC Decreased Platelet count Renal Impairment Hyperpigmentation Flushing G.I. upset Uveitis Painful pink eye Arthralgias Joint pain Uveitis When given in higher doses with drugs that decrease renal clearance Hold rifabutin until symptoms resolve Consider referral to ophthalmologist to rule-out other cause If infection is ruled-out, steroid eye drops may be used If recurring uveitis, stop rifabutin 24
25 Ethambutol Nausea Vomiting Loss of appetite Fever Headaches Dizziness Changes in visual acuity Changes in red/green color discrimination Managing & Monitoring Visual Toxicities Baseline & monthly visual acuity test (Snellen chart) Baseline & monthly color discrimination test (Ishihara tests) Question about visual disturbances including blurred vision Children to look for eye rubbing, excessive blinking, sitting close TV, difficulty with accurate grasping Hold EMB Refer for Ophthalmologic evaluation Permanent vision impairment if Rx continued 25
26 Snellen Eye Charts You will need: Ishihara Test Ishihara s Tests for Colour Deficiency 24 Plate Edition Well lit room(natural day light is preferred) Comfortable chair for patient Quiet room 26
27 Ishihara Plate Examples Case Study INH Resistant TB 21 year old male diagnosed with PTB CXR showed LUL cavitary infiltrate, AFB smear Cx (+) On October 2012: RIPE started Isolate reported Resistant to INH and Streptomycin INH discontinued once susceptibilities were known, Pt. continued on RIF, PZA, EMB to complete 9 months of adequate therapy 27
28 Case Study EMB Side Effects What Toxicities is a patient on EMB at risk for? Optic Neuritis Decreased visual acuity Decreased red-green color discrimination Case Study Vision Monitoring What baseline testing should you do for your patient who is starting EMB? Visual Acuity (Snellen) Ishihara 28
29 Case Study - Ophthalmic Toxicity 5 months after treatment initiation patient c/o difficulty driving and reading road signs As a nurse managing this patient s anti-tb therapy, what would you do? To assess vision screen Stop the EMB Refer to the Ophthalmologist Case Study Follow Up Patient contacted nurse by phone, she instructed him to see his eye doctor. He was seen by optometrist and given corrective lenses. EMB was continued 29
30 Case Study Visual Monitoring Results 7 months on anti-tb therapy he complains of worsening vision. Nurse finally assess his vision Baseline visual acuity in October: 20/20 both eyes Follow up visual acuity: 20/200 in both eyes. EMB was discontinued Pt. continued on RIF, PZA Levofloxacin was added to complete 9 mo of treatment Referral to a retinal specialist. Case Study Conclusion During the last two months of treatment pt evaluated by retinal specialist DX: EMB optic neuropathy Central scotoma on right and parascotoma on left Vision uncorrected: 20/200 Nurse admitted to not performing visual acuity screening (Snellen chart), she only did color discrimination testing (Ishihara plates) 30
31 Musculoskeletical Adverse Effects Arthralgia with First Line Drugs INH G.I. upset Peripheral neuropathy Mild CNS Toxicity PZA G.I. upset Arthralgias Gout (rare) Rifampin G.I. upset Thrombocytopenia, hemolytic anemia Renal toxicity Flu-like syndrome Orange staining of body fluids Ethambutol Optic Neuritis Rifabutin /Skin discoloration Leukopenia Thrombocytopenia Uveitis Arthralgias 31
32 Arthralgia With Second Line Drugs Amikacin Rash Renal toxicity Ototoxicity Vestibular toxicity Electrolyte abnormalities (hypokalemia, hypomagnesemia) Local Pain at the injection site Levofloxacin, Moxifloxacin GI upset (rare) Mild CNS toxicity Arthralgias, rare tendon rupture Photosensitivity EKG abnormalities Capreomycin Renal Toxicity Ototoxicity Vestibular Toxicity Electrolyte abnormalities (hypokalemia, hypocalcemia, hypomagnesemia) Local pain at the injection site Ethionamide GI upset, may be significant Endocrine effects (gynecomastia, hair loss, acne, impotence, menstrual irregularity, reversible hypothyroidism) Peripheral neuropathy Musculoskeletal Adverse Effects Aches, Pains, Myalgias, Arthralgias Usually not necessary to D/C meds NSAIDS can be helpful If acute swelling, erythema, warmth present, evaluate for infection, gout PZA rarely increase in uric acid gout except in patients with pre-existing gout or decreased renal function 32
33 33
34 Sources: CDC Core Curriculum on TB: What the Clinician Should Know; 5 th edition TB Nursing: A Comprehensive Guide to Patient Care; 2 nd Edition Drug- Resistant TB: A Survival Guide for Clinicians; 2 nd Edition; Curry International TB Center TB Drug Information Guide 2 nd Edition; Curry International TB Center _details.cfm?productid=wpt-17a 34
35 35
TB Nurse Case Management San Antonio, TX. TB Medications and Adverse Effects
TB Nurse Case Management San Antonio, TX April 1 3, 2014 TB Medications and Adverse Effects Debbie Onofre RN, BSN Nurse Consultant/ Nurse Educator Heartland National TB Center April 1, 2014 Debbie Onofre,
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Managing Anti-TB Therapy Side Effects and Complications Lisa Armitige, MD, PhD May 9, 2012 Lisa Armitige, MD, PhD has the following
More informationDebbie Onofre, RN, BSN March 18, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas
Managing and Monitoring Side Effects and Toxicities of Anti TB Therapy Debbie Onofre, RN, BSN March 18, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION
More informationAnti Tuberculosis Medications: Side Effects & adverse Events
Anti Tuberculosis Medications: Side Effects & adverse Events Diana Fortune, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Diana Fortune, RN,
More informationTB Nurse Case Management
TB Nurse Case Management San Antonio, Texas March 2-4, 2011 TB Medications and Adverse Effects Debbie Onofre, RN, BSN March 3, 2011 Debbie Onofre, RN, BSN has the following disclosures to make: No conflict
More informationIntroduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015
Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 TB Medications and Adverse Drug Events Presented by Evelyn Drzymala, RN, BSN February 11, 2015 Evelyn Drzymala, RN, BSN has
More informationManaging the Patients Response to TB Treatment
Managing the Patients Response to TB Treatment Barbarah Martinez, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Barbarah Martinez, RN, BSN has
More informationIntroduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015
Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 Initiation Phase Part 1 Ginny Dowell, RN, BSN February 4, 2015 Ginny Dowell RN, BSN has the following disclosures to make:
More informationDrug Interactions Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
More informationStandard TB Treatment
Standard TB Treatment Chris Keh, MD TB Controller, TB Prevention and Control Program, San Francisco Department of Public Health Assistant Clinical Professor, Division of Infectious Diseases, University
More informationManaging and Monitoring Side Effects and Toxicities of Anti TB Therapy Iris Barrera, RN April 11, 2018
Managing and Monitoring Side Effects and Toxicities of Anti TB Therapy Iris Barrera, RN April 11, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Iris Barrera,
More informationShu-Hua Wang, MD, MPH &TM Assistant Professor of Medicine The Ohio State University
Shu-Hua Wang, MD, MPH &TM Assistant Professor of Medicine The Ohio State University For anti-tuberculosis medications: Describe clinical monitoring for adverse drug reactions Review specific drug side
More informationTuberculosis medications: adverse drug reactions
Tuberculosis medications: adverse drug reactions Rajesh M. Prabhu, M.D. Infectious Diseases Essentia Health, Duluth, MN July 25, 2017 2014 MFMER slide-1 No Finanial Disclosures Learning Objectives 1. Describe
More informationDrug Side Effects and Toxicity
Drug Side Effects and Toxicity Gwen A. Huitt, MD MS Professor, Division of Mycobacterial and Respiratory Infections National Jewish Health Disclosures None Toxicity Nausea and vomiting Any Drug Can Cause
More information6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None
TB TREATMENT Bijan Ghassemieh, MD Seattle TB Clinical Intensive 2018 Disclosures None 1 Objectives Understand the following Rationale and goals for standard TB regimen When to initiate TB treatment Standard
More informationDRUG SIDE EFFECTS AND TOXICITY
DRUG SIDE EFFECTS AND TOXICITY Gwen A. Huitt, MD MS Professor, Division of Mycobacterial and Respiratory Infections National Jewish Health Disclosures None Objectives After participating in this lecture,
More informationTreatment of Tuberculosis
TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features
More informationTreatment: First Line Drugs TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS TREATMENT: GENERAL PRINCIPLES MECHANISM OF ACTION MID 27
TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS Treatment: First Line Drugs 1. ISONIAZID = INH Bacteriocidal against dividing organisms Dose = 300mg = one pill = well absorbed Good CNS penetration Can be
More informationDana G. Kissner, MD Detroit Department of Health & Wellness Promotion Wayne State University
Dana G. Kissner, MD Detroit Department of Health & Wellness Promotion Wayne State University I reply to those who urge me to take medicine that they should wait at least until I am restored to my strength
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationTreatment and Monitoring
Treatment and Monitoring Disclosures We have no actual or potential conflicts of interest in relation to this presentations. We have no financial relationships to disclose. Learning Objectives After this
More informationPeter Mere Latham English physician & educator
Poisons and medicine are oftentimes the same substance given with different intents Dana G. Kissner, MD Detroit Department of Health & Wellness Promotion Wayne State University Peter Mere Latham 1789-1875
More informationManagement of Patients with TB Infection Catalina Navarro, RN, BSN April 7, 2015
Management of Patients with TB Infection Catalina Navarro, RN, BSN April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Catalina Navarro,
More informationAnti Tuberculosis Medications
Anti Tuberculosis Medications Mary Ann Rodriguez, MD March 8, 2017 TB Nurse Case Management March 7 9, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Mary Ann Rodriguez, MD has the following disclosures
More informationWhat you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014
What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks
More informationLTBI Videos-Treatment
LTBI Videos-Treatment This program is presented by the Global Tuberculosis Institute and is based on recommendations from the Centers for Disease Control and Prevention. This is the third in a series of
More informationAntimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018
Antimycobacterial drugs Dr.Naza M.Ali lec 14-15 6 Dec 2018 About one-third of the world s population is infected with M. tuberculosis With 30 million people having active disease. Worldwide, 9 million
More informationMedication Administration and Adverse Reactions Alisha Blair, LVN September 28, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Medication Administration and Adverse Reactions Alisha Blair, LVN September 28, 2011 Alisha Blair, LVN, has the following disclosures to make:
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationTB Grand Rounds. Reynard McDonald, MD & Henry Fraimow, MD January 30, Outline
TB Grand Rounds Reynard McDonald, MD & Henry Fraimow, MD January 30, 2007 Outline Overview of 2006 ATS statement regarding hepatotoxicity of anti-tb therapy Case examples highlighting management of patients
More informationTB: A Supplement to GP CLINICS
TB: A Supplement to GP CLINICS Adverse Drug events With Anti Tuberculosis Therapy What Every GP Should Know Authors: Kavitha Saravu, MD, DNB, DTM&H; Madhukar Pai, MD, PhD Standards of TB Care in India
More informationTuberculosis Facts. TB is not spread by: Sharing food and drink Shaking someone s hand Touching bed lines or toilet seats
Tuberculosis Facts Below are frequently asked questions about TB, and their answers. If you have additional questions you may contact the City of Ennis Department of Health Services at 972-875-1234 or
More informationLTBI in Special Populations John Nava, MD October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 LTBI in Special Populations John Nava, MD October 5, 2010 2 Treatment of Latent TB Infection in Special Populations John
More informationSA TB Guidelines The interface with Advanced Clinical Care
SA TB Guidelines The interface with Advanced Clinical Care Dr Kogie Naidoo (MBCHB, PHD) Head: CAPRISA Treatment Research Programme Honorary Lecturer - UKZN Department of Public Heath Medicine Annual Workshop
More informationPediatric TB Intensive San Antonio, Texas October 14, 2013
Pediatric TB Intensive San Antonio, Texas October 14, 2013 Treatment of Tuberculosis in Children Jeffrey R. Starke, M.D. Professor of Pediatrics October 14, 2013 Jeffrey R. Starke, M.D. has the following
More informationTB Nurse Assessment. Ginny Dowell, RN, BSN October 21, 2015
TB Nurse Assessment Ginny Dowell, RN, BSN October 21, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19-22, 2015 Wichita, KS EXCELLENCE EXPERTISE INNOVATION Ginny Dowell,
More informationDrug Resistant Tuberculosis Self-reporting of Drugrelated. During Treatment
Drug Resistant Tuberculosis Self-reporting of Drugrelated Adverse Events During Treatment Introduction This information has been prepared for people with tuberculosis (TB) that is resistant to the commonly
More informationAt the end of this session, participants will be able to:
Advanced Concepts in Pediatric TB: Treatment of Tuberculosis Disease Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [with help from Andrea Cruz, M.D.] Objectives At the end
More informationDose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016
Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016 TB Nurse Case Management September 7-9, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Jessica Quintero, M.Ed., has the following disclosures
More informationOfficial ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (Nahid et al, CID 2016)
Official ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (Nahid et al, CID 2016) APPENDIX C: DRUGS IN CURRENT USE The U.S. Food and Drug Administration (FDA) has approved
More informationFor the Patient: Ponatinib Other names: ICLUSIG
For the Patient: Other names: ICLUSIG (poe na' ti nib) is a drug that is used to treat some types of cancer. It is a tablet that you take by mouth. The tablet contains lactose. Tell your doctor if you
More informationDexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.
Dexamethasone Other Names: Decadron About This Drug Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Possible Side Effects (More Common) Increased
More informationNivolumab. Nivolumab
Nivolumab Nivolumab This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary: for some people immunotherapy may reduce the risk of the cancer coming back, for
More informationDisclosures. Outline. No disclosures or conflicts of interest to report. Special LTBI situations. H t it d id ff t
Selected Topics in LTBI June 2, 2015 Bijan Ghassemieh, MD Senior Fellow UW Division of Pulmonary/Critical Care Disclosures No disclosures or conflicts of interest to report Outline Special LTBI situations
More informationTreatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015
Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationATORIS 10, 20, 40 mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER ATORIS 10, 20, 40 mg film-coated tablets ATORVASTATIN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationPATIENT INFORMATION LEAFLET POLLENTYME S AND TABS
SCHEDULING STATUS: S1 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: POLLENTYME TABLETS (tablets) POLLENTYME S (syrup) Read all of this leaflet carefully because it contains important information
More informationTB Nurse Case Management San Antonio, Texas April 9-11, 2013
TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB / Dose Counting Rachel Munoz, RN. TB Nurse Case Manager/Nurse Consultant Austin/Travis County Health Department April 10, 2013 Rachel Munoz,
More informationManaging MDR TB Treatment Side Effects
Managing MDR TB Treatment Side Effects Barbara J. Seaworth, M.D. Medical Director Heartland National TB Center Pacific Islands TB Controllers Association Conference, September 14, 2017 Honolulu, Hawaii
More informationTreatment of Latent TB Infection (LTBI)
Treatment of Latent TB Infection (LTBI) Mahesh C. Patel, MD June 14, 2017 2014 MFMER slide-1 Mahesh C. Patel, MD Associate Professor Treatment of LTBI Department of Internal Medicine, Division of Infectious
More informationMANAGEMENT OF DILI in TB/HIV coinfected patients. Chimoio 31 August 2017 by Dr Ndiviwe Mphothulo
MANAGEMENT OF DILI in TB/HIV coinfected patients Chimoio 31 August 2017 by Dr Ndiviwe Mphothulo ANTI-TB drugs Groups Drugs Group 1: First-line oral drugs Ethambutol (Emb) Pyrazinamide(PZA) Isoniazid (INH)
More informationCase Management of the TB/HIV Infected Patient
TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected
More informationTips and Tricks for Diagnosing and Treating Tuberculosis
Tips and Tricks for Diagnosing and Treating Tuberculosis Bob Belknap M.D. Director, Denver Metro TB Program December 6, 2017 DenverPublicHealth.org @DenverPublicHealth @DenPublicHealth Disclosures No conflicts
More informationWhat is the most important information I should know about bortezomib? What should I discuss with my healthcare provider before receiving bortezomib?
1 of 5 6/10/2016 3:46 PM Generic Name: bortezomib (bor TEZ oh mib) Brand Name: Velcade What is bortezomib? Bortezomib interferes with the growth of some cancer cells and keeps them from spreading in your
More informationDiscussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor
Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor TECENTRIQ DISCUSSION SUPPORT What is TECENTRIQ? TECENTRIQ is a prescription medicine used to treat: A type of bladder
More informationFor the Patient: Trastuzumab emtansine Other names: KADCYLA
For the Patient: Trastuzumab emtansine Other names: KADCYLA Trastuzumab emtansine (tras tooz' ue mab em tan' seen) is a drug that is used to treat some types of cancer. Trastuzumab emtansine is a clear
More informationFor the Patient: Fludarabine injection Other names: FLUDARA
For the Patient: Fludarabine injection Other names: FLUDARA Fludarabine (floo-dare-a-been) is a drug that is used to treat many types of cancer. It is a clear liquid that is injected into a vein. Tell
More informationAntituberculous Agents
Antituberculous Agents Primary or First Line Drugs: Isoniazid (INH) Rifampin Rifadin or Rimactane Ethambutal Streptomycin Pyrazinamide Isoniazid(INH) Most active. Small molecule, water soluble, Structurally
More informationNURSING PROCESS FOCUS: Patients Receiving Amphotericin B (Fungizone, Abelcet)
NURSING PROCESS FOCUS: Patients Receiving Amphotericin B (Fungizone, Abelcet) ASSESSMENT Prior to administration: Obtain complete health history including allergies, drug history, and possible drug interactions.
More informationPATIENT INFORMATION LEAFLET AMLOC RANGE
SCHEDULING STATUS: S3 PROPRIETARY NAME AND DOSAGE FORM: AMLOC 5 mg tablets AMLOC 10 mg tablet Read all of this leaflet carefully before you start taking AMLOC. Keep this leaflet. You may need to read it
More informationPATIENT INFORMATION LEAFLET
PPM Code: E1981 PATIENT INFORMATION LEAFLET SCHEDULING STATUS: S2 PROPRIETARY NAME DOSAGE FORM: film coated tablets Read all of this leaflet carefully because it contains important information for you.
More informationFor the Patient: USMAVFIPI
For the Patient: USMAVFIPI Other Names: First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab U = Undesignated (requires special request) SM = Skin and Melanoma AV = Advanced F =
More informationMethotrexate. About This Drug. Possible Side Effects. Warnings and Precautions
Methotrexate About This Drug Methotrexate is used to treat cancer. This drug is given in the vein (IV). Possible Side Effects Soreness of the mouth and throat. You may have red areas, white patches, or
More informationNew Patient Specialty Intake Form Department of Surgery
This form contains questions specific to the Department of Surgery. If you are new to Baylor College of Medicine and have not been seen in any of our offices, please be sure to complete our New Patient
More informationPRODUCT MONOGRAPH. FLOCTAFENINE Floctafenine Tablets 200 mg and 400 mg THERAPEUTIC CLASSIFICATION. Anti-inflammatory, Analgesic
0 PRODUCT MONOGRAPH FLOCTAFENINE Floctafenine Tablets 200 mg and 400 mg THERAPEUTIC CLASSIFICATION Anti-inflammatory, Analgesic INFORMATION FOR THE PATIENT FLOCTAFENINE, which has been prescribed to you
More informationPATIENT INFORMATION LEAFLET CARZIN XL
SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: 4 mg film coated tablets. Read all of this leaflet carefully before you start taking. Keep this leaflet. You may need to read it
More informationPOLLENTYME S and Tabs Pharma Dynamics (Pty) Ltd Version: July 2017 (G1639) Word copy of G1639 PATIENT INFORMATION LEAFLET FOR POLLENTYME S AND TABS
PROPOSED FINAL PATIENT INFORMATION LEAFLET FOR POLLENTYME TABLETS & POLLENTYME S PATIENT INFORMATION LEAFLET SCHEDULING STATUS: S1 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: POLLENTYME TABLETS
More informationPatient Name: Date: Address: Primary Care Physician: Online Website On TV In print On the radio
927 W. Myrtle St. Boise, ID 83702 (208) 947-0100 NEW PATIENT INTAKE Patient Name: Date: Email Address: Primary Care Physician: How did you hear about AVT? (Please mark all that apply) Online Website On
More informationFor the Patient: Adjuvant therapy for breast cancer using weekly paclitaxel and trastuzumab (Herceptin)
For the Patient: Adjuvant therapy for breast cancer using weekly paclitaxel and trastuzumab (Herceptin) Other names: UBRAJTTW U Undesignated BR Breast AJ Adjuvant T Trastuzumab (HERCEPTIN ) TW Paclitaxel
More informationUpdate on Management of
Update on Management of DR TB Definitions Presumptive MDR-TB A patient suspected of drug-resistant TB, based on RNTCP criteria for submission of specimens for drug-susceptibility testing MDR-TB Case A
More informationPatient Information IXEMPRA Kit (pronounced as ǐk-'sĕm-pră) (ixabepilone) What is the most important information I should know about IXEMPRA?
17.6 FDA-Approved Patient Labeling Patient Information IXEMPRA Kit (pronounced as ǐk-'sĕm-pră) (ixabepilone) for Injection, for intravenous infusion only Read the Patient Information that comes with IXEMPRA
More informationIrbenida H 150mg/12,5mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Irbenida H 150mg/12,5mg film-coated tablets IRBESARTAN/HYDROCHLOROTHIAZIDE This leaflet is a copy of the Summary of Product Characteristics and Patient Information
More informationTreatment of Tuberculosis, 2017
Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,
More informationTB Drugs. Discuss the common route for transmission of the disease. Discusses the out line for treatment of tuberculosis.
TB Drugs Red : important Black : in male / female slides Pink : in female s slides only Blue : in male s slides only Females doctor notes Grey: Males doctor notes OBJECTIVES: By the end of this lecture,
More informationAmarillo Surgical Group Doctor: Date:
Office Visit Information (General Surgery) Amarillo Surgical Group Doctor: Date: Patient s Information Name: Last First Middle Social Security #: Date of Birth: Age Gender: [ Male / Female ] Marital Status:
More informationWhat is the most important information I should know about tenofovir? What should I discuss with my healthcare provider before taking tenofovir?
1 of 6 6/10/2016 4:33 PM Generic Name: tenofovir (ten OF oh vir) Brand Name: Viread What is tenofovir? Tenofovir is an antiviral medicine that prevents human immunodeficiency virus (HIV) or hepatitis B
More informationFor the Patient: USMAVPEM
For the Patient: USMAVPEM Other Names: Treatment of Unresectable or Metastatic Melanoma Using Pembrolizumab U = Undesignated (requires special request) SM = Skin and Melanoma AV = Advanced PEM = Pembrolizumab
More informationPediatric TB Lisa Armitige, MD, PhD September 28, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.
More informationJoseph S. Weiner, MD, PC Patient History Form
Date: / / NAME: Last First M. I. Age: Sex: q F q M Birthdate: / / What specific questions or goals do you have for this appointment? Please list the names of other clinicians you have seen for this problem:
More informationFor the Patient: Cyclosporine injection Other names: SANDIMMUNE I.V.
For the Patient: Cyclosporine injection Other names: SANDIMMUNE I.V. Cyclosporine (sye kloe spor een) is a drug that may be used to treat certain types of cancer. It may also be used to suppress your immune
More informationTuberculosis: A Provider s Guide to
Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency
More informationPROBLEMS IN TX CASE STUDY. JB is a 42 yo BM who was admitted to
Why TB Drugs Fail Part 2 Why TB Drugs Fail OR How We Fail TB Drugs (and Tb Patients) 1 PROBLEMS IN TX FAILURE TO RESPOND TB MENINGITIS RENAL FAILURE HEPATITIS CAN T SWALLOW PILLS GI INTOLERANCE ADVERSE
More informationGLEEVEC PATIENT RESOURCES
GLEEVEC TALKING WITH YOUR DOCTOR ABOUT KIT+ GIST AND ITS TREATMENT When you have KIT-positive gastrointestinal stromal tumor (KIT+ GIST), you will likely have many questions and may, at times, feel overwhelmed
More informationEtiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition
Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis
More informationFor the Patient: Paclitaxel Other names: TAXOL
For the Patient: Paclitaxel Other names: TAXOL Paclitaxel (pak'' li tax' el) is a drug that is used to treat many types of cancer. It is a clear liquid that is injected into a vein. Tell your doctor if
More informationPlease describe, in detail, when the symptoms began:
161 East Mallard Drive, Suite 130, Boise, ID 83706 (208) 947-0100 New Patient Intake Patient Name: Primary Care Physician: Date: Email address: How did you hear about AVT (mark all that apply) Online On
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET PROSTATIN (OCTREOTIDE ACETATE INJECTION 10mcg, 50mcg) Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again.
More informationFor the Patient: Bendamustine Other names: TREANDA
For the Patient: Bendamustine Other names: TREANDA Bendamustine (ben'' da mus' teen) is a drug that is used to treat some types of cancer (lymphoma). It is a clear liquid that is injected into a vein.
More informationTuberculosis (TB) how do we treat it?
Tuberculosis (TB) how do we treat it? Read this. Here is how you will be cured. You will be cured if you take your medicines every day during the whole treatment. You are not alone, let s do this together!
More informationTrastuzumab and Lapatinib
PATIENT EDUCATION patienteducation.osumc.edu What is Trastuzumab (tras-too-zoo-mab) and how does it work? Trastuzumab is a type of targeted cancer therapy called a monoclonal antibody. Another name for
More informationPediatric TB Intensive Houston, Texas
Pediatric TB Intensive Houston, Texas November 13, 2009 Treatment of Pediatric TB Jeffrey R. Starke, M.D. November 13, 2009 MANAGEMENT OF CHILDHOOD TUBERCULOSIS Jeffrey R. Starke, M.D. Professor of Pediatrics
More informationWHOPAR part 3 Suppliers submission of the SRA approved text. Package Leaflet: Information for the user
Package Leaflet: Information for the user Ethambutol Atb 250 mg Ethambutol hydrochloride Ethambutol Atb 400 mg Ethambutol hydrochloride Read all of this leaflet carefully before you start using this medicine
More informationSharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center
TB Infection Diagnostics and Treatment Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention 1 Curry International
More informationRHEUMATOLOGY PATIENT HISTORY FORM
!! RAMOS RHEUMATOLOGY, PC RHEUMATOLOGY PATIENT HISTORY FORM Date: / / NAME: Birthdate: / / Last First M. I. Age: Sex: F M Marital status: Never married Married Divorced Separated Widowed Partnered/significant
More informationFor the Patient: Cobimetinib tablets Other names: COTELLIC
For the Patient: Cobimetinib tablets Other names: COTELLIC Cobimetinib (koe" bi me' ti nib) is a drug that is used to treat some types of cancer. It is a tablet that you take by mouth. The tablet contains
More information